Samsung Electronics
Search results
12 hours ago · Samsung Biologics is a fully integrated CDMO with qualified and highly innovative contract development, contract manufacturing, and biosafety testing services.
Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing.
Mar 31, 2023 · Samsung Biologics is a fully integrated, end-to-end CDMO service provider offering seamless development and manufacturing solutions from cell line development to final aseptic fill/finish as well as laboratory testing services at every stage for biopharmaceutical products.
Samsung Biologics is a fully integrated CDMO offering state-of-the-art contract development and manufacturing services.
Jul 3, 2024 · Samsung Biologics announced July 2 that it has signed a $1.06 billion contract with a U.S.-based pharmaceutical company for the contract manufacturing of biopharmaceuticals. This is the largest contract ever secured by a South Korean biotech company and represents 42% of Samsung Biologics’ total orders from last year.
Jun 20, 2024 · Samsung Biologics, LegoChem partner to propel ADC development and production. The CDMO credited its growth on the operation of its Plant 4 facility, plus growing sales from its biosimilar...
Mar 21, 2022 · Samsung Biologics, the biopharmaceutical unit of South Korea’s Samsung Group, is seeking to build its first plants in the US and Europe as it rebalances its global supply chains...
Mar 31, 2023 · Find all Investor Relation materials, including our earnings release, stock chart, public disclosures, annual and business reports, and audited financial statements.
Jul 11, 2024 · Samsung C&T, a major shareholder of Samsung Biologics which has Samsung Bioepis as a 100% owned subsidiary, has chosen bio/healthcare areas as a sustainable growth engine and the investment in the Flagship Pioneering Fund VIII perfectly matches our mid-term growth strategy,” said Jaywoo Kim, executive vice president, Samsung C&T Corporation. “We look forward to having more investment opportunities in future technologies that go beyond the limitations of conventional healthcare and ...
Mar 2, 2023 · Two years after burgeoning CDMO powerhouse Samsung Biologics signed on to manufacture COVID-19 vaccines for Moderna, the Korean company has made a deal with the world’s other leading mRNA ...
